Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.4M
-
Number of holders
-
189
-
Total 13F shares, excl. options
-
79.3M
-
Shares change
-
+13M
-
Total reported value, excl. options
-
$3.01B
-
Value change
-
+$505M
-
Put/Call ratio
-
9.75
-
Number of buys
-
108
-
Number of sells
-
-76
-
Price
-
$37.92
Significant Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) as of Q3 2025
209 filings reported holding MLYS - Mineralys Therapeutics, Inc. - Common Stock as of Q3 2025.
Mineralys Therapeutics, Inc. - Common Stock (MLYS) has 189 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 79.3M shares
.
Largest 10 shareholders include Catalys Pacific, LLC (8.9M shares), RA CAPITAL MANAGEMENT, L.P. (7.32M shares), SAMSARA BIOCAPITAL, LLC (6.26M shares), BlackRock, Inc. (3.67M shares), VANGUARD GROUP INC (3.02M shares), Caligan Partners LP (2.77M shares), Capital International Investors (2.39M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (2.13M shares), SR One Capital Management, LP (2.11M shares), and FMR LLC (2.07M shares).
This table shows the top 189 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.